Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2023 | $3.00 → $4.00 | Speculative Buy → Buy | The Benchmark Company |
10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)
HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Jim Green, Chairman and CEO said, "Originally joining us as our Vice President of Global Finance, Jennifer brought extensive experience in areas including global financial and operational leadership, corporate strategy, accounting and internal controls, and strong fiscal management. Since assuming the
HOLLISTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, "Our third quarter revenues continued to reflect the effects of the challenging market environment. Our migration to a single US enterprise resource planning system, completed in the third quarter, supports operating efficiencies as well as improvements in inventory and supply chain management going forward. We have stayed focused on managing costs and have implemented additional cost reduction actions that we expect to result in incremental quarterly cost savings of
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presenta
HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, "Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented during Q2 are expected to drive annualized savings of approximately $4 million while we continue our work on new product development and growth initiatives." Green continued, "We believe the market recovery is likely delayed to later in the second half however we rema
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
HOLLISTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, "Our third quarter revenues continued to reflect the effects of the challenging market environment. Our migration to a single US enterprise resource planning system, completed in the third quarter, supports operating efficiencies as well as improvements in inventory and supply chain management going forward. We have stayed focused on managing costs and have implemented additional cost reduction actions that we expect to result in incremental quarterly cost savings of
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presenta
HOLLISTON, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity monitoring system. MCS™ Mesh MEA™ Organoid Platform The Company will exhibit its organoid-centric mesh Microelectrode Array (MEA) platform, which continues to gain traction among the scientific and therapy development communities. Unlike traditional technologies
The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Harvard Bioscience The Trade: Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO James W Green bought a total of 10,000 shares at an average price of $2.91. To acquire these shares, it cost around $29,100. What's Happening: On May 7, Harvard Bioscience poste
The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Harvard Bioscience The Trade: Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO James W Green bought a total of 20,000 shares at an average price of $3.07. To acquire these shares, it cost around $61,400. What's Happening: On May 7, Harvard Bioscience poste
For the full year 2024 revenues to be approximately flat versus 2023. Company sees second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. The company seest 2024 gross margin of approximately 60% and adjusted EBITDA margin in the mid-teens.
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously
KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)